Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibody
Biotech
Kaken strengthens late-stage HAE portfolio with $32M Astria deal
Kaken Pharmaceutical is paying $16 million upfront for the Japanese rights to Astria Therapeutics’ phase 3-stage hereditary angioedema drug.
James Waldron
Aug 6, 2025 10:21am
Novartis' ianalumab fails to show promise in dermatology study
Jul 17, 2025 4:28am
Amgen, Zai say stomach cancer candidate hits phase 3 mark
Jun 30, 2025 10:36am
Alphabet's Calico weaves anti-aging deal with China's Mabwell
Jun 26, 2025 4:52pm
Invivyd says Pemgarda sequel could be alternative to COVID shots
Jun 26, 2025 10:12am
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
